This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.


Advertisement


 Mobile version  RSS  Subscribe  Unsubscribe  Archive  Media Kit

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us   Nov. 1, 2013


Advertisement

Advertisement
 

Advertisement


SOCIETY NEWS


Deadline extended! Submit your abstract for AST's Cutting Edge of Transplantation 2014 and register today
AST
AST presents the Cutting Edge of Transplantation Feb. 13-15, 2014, at the Sheraton Wild Horse Pass in Chandler, AZ. Submit your basic, clinical or translational abstract Submit your basic, clinical or translational abstract related to the CEOT 2014 meeting topic: "Optimizing Long-Term Transplant Survival: Therapeutics, Targets, Technologies." Abstracts will be presented in mini-oral and/or poster format. All abstracts presented at CEOT will receive focused attention and constructive feedback from attendees and faculty. View the preliminary program  now to see what will be covered, and check back often as expert faculty are being announced soon. Registration opens today! Register by Nov. 30 and get HALF OFF regular rates!
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement


AST member awarded FDA grants to study immunosuppression
AST
The AST is pleased to announce that Rita R. Alloway, PharmD, was recently awarded two grants from the FDA to conduct studies related to the pharmacokinetics of various tacrolimus formulations. The first study compares the pharmacokinetic parameters of the most disparate generic formulations to brand in kidney and liver transplant recipients, while the second study evaluates the switchability between all tacrolimus formulations in high risk transplant recipients.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


T3: Register now for IPITA conference summary webinar on Nov. 19
AST
Webinars for the Timely Topics in Transplantation series are broadcast live one Tuesday a month at 2 p.m. EST. The next webinar will focus on highlights from the recent International Pancreas & Islet Transplant Association World Congress. Mark your calendars for Tuesday, November 19 at 2 p..m EST to participate in this webinar. Webinars are free to AST members; however, pre-registration is required. Non-members may purchase access to any of the webinar for a fee of $25 each. Click here to register, members just use your AST username and password during registration to waive the fee!
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


PRODUCT SHOWCASE
  UCLA Immunogenetics Center

The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
 


AST Institutional Support Program
AST
  • Are you interested in receiving recognition and increased exposure for your transplant center?
  • Does your center support the future of transplantation and value the educational, networking, and research opportunities that the American Society of Transplantation (AST) provides to its members?
  • Does your center support AST's lobbying of the U.S. Congress and Federal Agencies to secure a more transplant provider friendly environment for patients and physicians?
If the answer to these questions is YES, please consider having your center participate in AST’s 2014 Institutional Support Program. With a charitable contribution of $3,000 to support AST's research, professional education, and advocacy programs, your center will receive valuable benefits.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




TRANSPLANT NEWS


The impact of mean first-year heart rate on outcomes after heart transplantation: does it make a difference?
Clinical Transplantation
Cardiac denervation following transplantation has a variable effect on heart rate (HR), and the consequence of this is not known. We examined the impact of first-year HR on five-year outcomes after heart transplant. Mean first-year HR does not provide prognostic significance for one-year freedom from treated rejection, five-year survival or development of CAV five year after heart transplant. These results suggest that HR post-heart transplantation does not affect long-term outcomes, but high first-year HRs may be associated with new-onset CHF.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Research: Teens have an increased risk of kidney transplant failure
By Joy Burgess
A group of researchers at the University of Florida in Gainesville analyzed the data of more than 168,000 first kidney-only transplants between October 1987 and October 2010. According to the research published in JAMA Internal Medicine, teenagers between 14 and 15 years of age have a much higher risk of transplant failure after kidney transplantation than adults. The study shows that adolescents are more likely to have the kidney stop working than both older and younger transplant recipients.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Featured Advertisers


Advertisement


Astellas is entering its 20th year focusing on transplant immunology. Today we remain steadfast in our commitment to advancing the field. Tomorrow we will seek new possibilities to help improve the transplant experience. Together. Please visit astellas.us
Advertisement
University of Vermont Transplant Nephrologist

The University of Vermont/Fletcher Allen Health Care is seeking applications for a senior faculty member to join the Division of Nephrology. The candidate should be UNOS certified in kidney and pancreas transplants, experienced in educating nephrology fellows, growing transplant programs, and providing administrative leadership. Apply Here
Amnis
The FlowSight offers high performance in a small package. Its innovative design increases signal and minimizes noise to provide unmatched fluorescence sensitivity. Twelve standard detection channels simultaneously produce brightfield, darkfield and up to ten channels of fluorescence imagery of every cell. More info


Elevated bronchoalveolar lavage eosinophilia correlates with poor outcome after lung transplantation
Transplantation (login reqiured)
Eosinophils are involved in the pathophysiology of many respiratory diseases, but the exact role of eosinophilia in lung transplantation has not been thoroughly investigated. performed a retrospective analysis of our transplanted patients between 2001 and 2011, with a minimum follow-up of 1 year. Using a cutoff of 2 percent eosinophilia in bronchoalveolar lavage (BAL) fluid, chronic lung allograft dysfunction (CLAD)-free survival and overall survival was compared between 66 patients demonstrating at least one BAL with eosinophils of 2 percent and 253 control patients.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Measuring and explaining racial and ethnic differences in willingness to donate live kidneys in the United States
Clinical Transplantation
Reasons for US racial–ethnic minority ESRD patients' reported difficulties identifying live kidney donors are poorly understood. We conducted a national study to develop scales measuring willingness to donate live kidneys among US adults (scores ranged from 0 [not willing] to 10 [extremely willing]), and we tested whether racial–ethnic differences exist in willingness to donate. We also examined whether clinical, sociodemographic, and attitudinal factors mediated potential racial–ethnic differences in willingness.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Diagnose faster, when it matters most.
For nearly 30 years, physicians have trusted Viracor-IBT Laboratories to provide accelerated results, specialized expertise and exceptional service in transplant testing. Learn more at www.viracoribt.com.
Advertise here!

To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE


Solid tumors following kidney transplantation in children
Pediatric Transplantation (login required)
Kidney transplant recipients have an increased risk of cancer. Data on non-LPD malignancies (solid tumors) in pediatric renal transplant recipients are limited. We performed a cohort study using the NAPRTCS transplant registry to describe the incidence of non-LPD malignancy compared with the general pediatric population. In this first large-scale study of North American pediatric renal transplant recipients, we observed a 6.7-fold increased risk of non-LPD malignancy compared with the general pediatric population. Further examination of this unique patient population may provide greater insight into the impact of transplant and immunosuppression on malignancy risk.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Peripheral blood biomarkers for the characterization of alloimmune reactivity after pediatric liver transplantation
Pediatric Transplantation (login required)
Individualization of immunosuppressive medications is an important objective in transplantation medicine. Reliable biomarkers to distinguish between patients dependent from intensive immunosuppressive therapy and those where therapy can be minimized among pediatric transplant recipients receiving immunosuppressive medications are still not established. We evaluated the potential of cross-sectional quantification of regulatory T cells, lymphocyte subsets, and cytokine concentrations as biomarkers in 60 pediatric liver transplant recipients with AR, CR, or normal graft function and in 11 non-transplanted patients. Transplant recipients presenting with AR had significantly higher CD8+ T-cell counts, significantly higher concentrations of IL-2, an
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    Study: Kidney transplant rejection drugs tied to pregnancy risks (HealthDay News via U.S. News and World Report)
Independent risk factors for urinary tract infection and for subsequent bacteremia or acute cellular rejection (Transplantation)
Transplant Surgeons: Meet your ABS MOC requirements through the AJT (American Journal of Transplantation (login required))
Research: Old cancer drug may help prevent rejection after transplantation (By Joy Burgess)
Screening for new-onset diabetes after kidney transplantation: Limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin (Transplantation)

Don't be left behind. Click here to see what else you missed.




Alemtuzumab induction with tacrolimus monotherapy in 25 pediatric renal transplant recipients
Pediatric Transplantation (login required)
ALA induction in transplantation has been shown to reduce the need for maintenance immunosuppression. We report the outcome of 25 pediatric renal transplants between 2007 and 2010 using ALA induction followed by tacrolimus maintenance monotherapy. Patient ages were 1–19 yr (mean 14 ± 4.1 year). Time of follow-up was 7–51 months (mean 26 ± 13 months). Tacrolimus monotherapy was maintained in 48 percent of patients, and glucocorticoids were avoided in 80 percent of recipients.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Courtney Hodges, Content Editor, 972.402.2604   
Contribute news


This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Oct. 25, 2013
Oct. 19, 2013
Oct. 11, 2013
Oct. 4, 2013






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063